Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Do you or your child have a platelet, bleeding, or white blood cell disorder? This study is looking at people who have platelet or other blood disorders. The researchers will use a blood sample to look for problems with platelets and a possible genetic cause in the participant’s DNA or RNA. To participate in this study, you must be a child or adult who either is healthy or has a platelet disorder, coagulation disorder, or white blood cell disorder. This study is located in New York, New York.

Are you an adult willing to give blood samples? This study investigates ways to prevent blood clotting in people with sickle cell disease. In this population, blood clotting is the most common cause of vascular death after heart attack and stroke. Scientists are studying the blood of people with sickle cell disease and comparing it with the blood of people without sickle cell disease over 2 years. To participate in this study, you must be between the ages of 18 and 80 years old and willing to participate for up to 2 years. This study takes place in Bethesda, Maryland.

The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed.

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.

This study will test the feasibility and acceptability of deploying a decision aid for surrogate decision makers of comatose survivors of cardiac arrest early during hospitalization.

The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed.

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.

Are you an adult with ischemic or non-ischemic cardiomyopathy? This observational study will group and follow patients at a higher risk for sudden cardiac death (SCD) who receive an implantable cardioverter defibrillator (ICD) pulse generator replacement as a prevention measure. The study hypothesizes that abnormalities of the heart, some of which are genetically determined, can be used to identify patients at high risk of SCD. To participate in this study, you must be between 18 and 85 years old and have ischemic or non-ischemic cardiomyopathy. You must also be getting your initial ICD implant for primary prevention or a programmed generator replacement if the ICD was originally implanted for SCD primary prevention. The study takes place in Baltimore, Maryland; Richmond, Virginia; and Washington, DC.

Are you an adult with ischemic cardiomyopathy? This study is investigating ways to prevent sudden cardiac arrest in people with ischemic cardiomyopathy. Researchers in this study are also working to determine which patients could benefit from an implantable cardioverter defibrillator, a device that is connected to the heart that can detect and stop irregular heartbeats called arrythmias. To participate in this study, you must be 18 years old or older and have ischemic cardiomyopathy. This study takes place in Buffalo, New York.